Not long ago, cell and gene therapies were considered experimental breakthroughs reserved for a handful of patients. Today, they represent one of healthcare’s most promising frontiers, offering the potential to treat—and in some cases cure—previously untreatable diseases. Yet while scientific progress continues at an incredible pace, manufacturing has become the biggest hurdle.

The biotechnology industry now faces a defining challenge: transforming highly personalized, small-scale production into reliable, commercial manufacturing without compromising quality, safety, or affordability. Industrializing cell and gene therapy isn’t simply about producing more doses. It’s about building an ecosystem capable of delivering life-changing treatments to thousands of patients around the world.

Why the Biotechnology Industry Must Move Beyond Small-Batch Manufacturing

Scientific innovation has advanced faster than manufacturing capabilities. Many therapies still rely on labor-intensive processes designed for clinical trials rather than commercial distribution.

Autologous therapies, which use a patient’s own cells, require individualized production runs. Every batch becomes unique, leaving little room for standardized workflows. Even allogeneic therapies, which use donor cells, introduce their own challenges around consistency, scalability, and regulatory oversight.

As more therapies receive regulatory approval, manufacturers must dramatically increase production capacity while maintaining the strict quality standards that define modern biopharmaceutical manufacturing.

The Biggest Scalability Challenges

Industrialization requires solving several interconnected challenges that affect every stage of production.

1. Complex Manufacturing Workflows

Cell and gene therapies involve multiple highly specialized processes, including cell isolation, genetic modification, expansion, purification, cryopreservation, and transportation.

Each step introduces variability, making process standardization significantly more difficult than traditional pharmaceutical manufacturing.

2. Supply Chain Complexity

Unlike conventional medicines, cell therapies often involve time-sensitive biological materials that must move between hospitals, manufacturing facilities, testing laboratories, and treatment centers.

Maintaining the chain of identity and chain of custody throughout the journey is critical. A single labeling error or temperature deviation can compromise an entire therapy.

3. High Production Costs

Manufacturing remains one of the largest contributors to therapy costs. Highly skilled labor, specialized cleanrooms, manual quality inspections, and limited production capacity all increase operating expenses. Lowering these costs without sacrificing product quality remains one of the industry’s highest priorities.

4. Regulatory Compliance at Scale

As production expands, regulatory expectations become even more demanding.

Manufacturers must demonstrate process consistency, complete traceability, data integrity, and rigorous quality control across every production batch. Scaling operations while satisfying evolving global regulations requires significant operational maturity.

Technology Is Redefining Cell & Gene Therapy Manufacturing

Fortunately, innovation is transforming manufacturing just as rapidly as it transformed the science itself. Automation reduces manual intervention, minimizes variability, and improves reproducibility across production workflows. Closed-system manufacturing platforms decrease contamination risks while increasing operational efficiency.

Artificial intelligence helps optimize production parameters, identify quality deviations earlier, and improve yield predictions. Meanwhile, digital twins simulate manufacturing environments, allowing engineers to test improvements before implementing them on the production floor.

Advanced analytics also provide real-time visibility into manufacturing performance, enabling faster decision-making and continuous process optimization.

Together, these technologies help the biotechnology industry move closer to scalable, commercially viable production.

Collaboration Will Determine Long-Term Success

No single organization can industrialize cell and gene therapy alone. Biopharmaceutical companies, technology providers, contract development and manufacturing organizations (CDMOs), healthcare providers, regulators, and logistics partners must work together to build standardized, interconnected ecosystems.

Industry-wide collaboration accelerates knowledge sharing, improves manufacturing standards, reduces development timelines, and strengthens global supply chains. As new partnerships emerge, organizations gain access to specialized expertise while avoiding costly infrastructure duplication. Ultimately, collaboration transforms innovation into accessible patient care.

ALSO READ: Overcoming the Scaling Bottlenecks of Wearable Medical Devices in RPM

The Road Ahead

Cell and gene therapies have already reshaped modern medicine. The next transformation will occur inside manufacturing facilities rather than research laboratories.

Organizations that invest in automation, digital technologies, standardized processes, and strategic partnerships will be best positioned to meet growing patient demand. Industrialization will not eliminate complexity, but it will make these groundbreaking therapies more accessible, more affordable, and more sustainable.

The future of the biotechnology industry depends not only on discovering the next medical breakthrough but also on building manufacturing systems capable of delivering those breakthroughs at global scale.